SAN DIEGO, Aug. 1, 2018 /PRNewswire/ -- Tocagen Inc.
(Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy
company, today announced it will report its second quarter 2018
financial results and business progress on Tuesday, August 7,
2018, after the close of the U.S. financial markets.
To receive Tocagen's press releases and other investor
information, please visit the Investor Relations page of the
company's website and register for email alerts.
About Tocagen
Tocagen is a clinical-stage,
cancer-selective gene therapy company developing first-in-class,
broadly applicable product candidates designed to activate a
patient's immune system against their own
cancer. Tocagen's lead investigational product candidate,
Toca 511 & Toca FC, is under evaluation in a pivotal Phase 3
trial for recurrent high grade glioma (HGG), a disease with
significant unmet medical need. The U.S. Food and Drug
Administration (FDA) has granted Toca 511 & Toca FC
Breakthrough Therapy Designation for the treatment of recurrent HGG
and the European Medicines Agency (EMA) has granted Toca
511 PRIME (PRIority MEdicines) designation for the treatment of
glioma. For more information about Tocagen,
visit www.tocagen.com.
Media Contact:
Pam
Lord
Canale Communications
(619) 849-6003
pam@canalecomm.com
Investor Contact:
Elizabeth
Broder
Endurance Advisors
ebroder@enduranceadvisors.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/tocagen-to-report-second-quarter-2018-financial-results-on-tuesday-august-7-300690486.html
SOURCE Tocagen Inc.